Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | FBP1 | P09467 | 1/20 | 0.48 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.47 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17969091 | 1.00 | TSHR (0.54) | TSHRALDH1A1AKR1C3RECQLFBP1 | |
| SCHEMBL26928883 | 0.80 | CYP2A6 (0.44) | ALDH1A1AKR1C3SMN1; SMN2KMT2AHTT | |
| SCHEMBL5078610 | 0.79 | TSHR (0.50) | TSHRALDH1A1AKR1C3RECQLFBP1 | |
| SCHEMBL295401 | 0.79 | TSHR (0.50) | TSHRALDH1A1AKR1C3RECQLFBP1 | |
| SCHEMBL110774 | 0.79 | TSHR (0.50) | TSHRALDH1A1AKR1C3RECQLFBP1 | |
| SCHEMBL5027068 | 0.79 | TSHR (0.50) | TSHRALDH1A1AKR1C3RECQLFBP1 | |
| SCHEMBL295402 | 0.79 | TSHR (0.50) | TSHRALDH1A1AKR1C3RECQLFBP1 | |
| SCHEMBL598599 | 0.79 | TSHR (0.50) | TSHRALDH1A1AKR1C3RECQLFBP1 | |
| SCHEMBL2910666 | 0.78 | RECQL (0.67) | TSHRALDH1A1AKR1C3RECQLFBP1 | |
| SCHEMBL2910667 | 0.78 | RECQL (0.67) | TSHRALDH1A1AKR1C3RECQLFBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219477-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2023-08-02 | — | — | EP | disclosed |
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
| US-9981008-B2 | Apolipoprotein A-I mimics | CERENIS THERAPEUTICS HOLDING SA (FR) | 2018-05-29 | — | — | US | disclosed |
| EP-2939683-B1 | Apolipoprotein A-I Mimics | CERENIS THERAPEUTICS HOLDING SA (FR) | 2017-01-04 | — | — | EP | disclosed |
| US-20160324923-A1 | APOLIPOPROTEIN A-I MIMICS | CERENIS THERAPEUTICS HOLDING SA (FR) | 2016-11-10 | — | — | US | disclosed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
| US-9388232-B2 | Apolipoprotein A-I mimics | CERENIS THERAPEUTICS HOLDING SA (FR) | 2016-07-12 | — | — | US | disclosed |
| EP-2939683-A1 | Apolipoprotein A-I Mimics | Cerenis Therapeutics Holding SA (FR) | 2015-11-04 | — | — | EP | disclosed |
| EP-2396017-B1 | APOLIPOPROTEIN A-I MIMICS | CERENIS THERAPEUTICS HOLDING SA (FR) | 2015-07-01 | — | — | EP | disclosed |
| US-20150141330-A1 | APOLIPOPROTEIN A-I MIMICS | CERENIS THERAPEUTICS HOLDING SA (FR) | 2015-05-21 | — | — | US | disclosed |
| US-8993597-B2 | Apolipoprotein A-I mimics | CERENIS THERAPEUTICS HOLDING SA (FR) | 2015-03-31 | — | — | US | disclosed |
| US-20130231459-A1 | APOLIPOPROTEIN A-I MIMICS | CERENIS THERAPEUTICS HOLDING SA (FR) | 2013-09-05 | — | — | US | disclosed |
| US-8378068-B2 | Apolipoprotein A-I mimics | CERENIS THERAPEUTICS HOLDING SA (FR) | 2013-02-19 | — | — | US | disclosed |
| EP-2396017-A1 | APOLIPOPROTEIN A-I MIMICS | Cerenis Therapeutics SA (FR) | 2011-12-21 | — | — | EP | disclosed |
| US-20100267631-A1 | APOLIPOPROTEIN A-I MIMICS | CERENIS THERAPEUTICS HOLDING SA (FR) | 2010-10-21 | — | — | US | disclosed |
| WO-2010093918-A1 | APOLIPOPROTEIN A-I MIMICS | CERENIS THERAPEUTICS SA (FR) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | TSHR 2067/4885ALDH1A1 1611/4885AKR1C3 888/4885 |
| US-20100267631-A1 | APOLIPOPROTEIN A-I MIMICS | APOB, APOL1, LIPG | TSHR 3416/4885ALDH1A1 3150/4885AKR1C3 3756/4885 |
| US-20160324923-A1 | APOLIPOPROTEIN A-I MIMICS | APOB, APOL1, LIPG | TSHR 3416/4885ALDH1A1 3150/4885AKR1C3 3756/4885 |
| US-20150141330-A1 | APOLIPOPROTEIN A-I MIMICS | APOB, APOL1, LIPG | TSHR 3416/4885ALDH1A1 3150/4885AKR1C3 3756/4885 |
| US-20130231459-A1 | APOLIPOPROTEIN A-I MIMICS | APOB, APOL1, LIPG | TSHR 3416/4885ALDH1A1 3150/4885AKR1C3 3756/4885 |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | CS, PC, ACAT1 | TSHR 2067/4885ALDH1A1 1611/4885AKR1C3 888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.